All News

podcast logo

RheumNow Podcast – ACR 20 is Coming to Town (10.30.20)

Jack Cush, MD

Dr Jack Cush overviews the RheumNow commitment, upcoming bonus coverage of ACR20 and the good news and journal reports from the past week on RheumNow.com

Read Article
colitis.jpg

Vedolizumab Promising in Immune-Related GI Events

Jack Cush, MD

Vedolizumab (Entyvio) was superior to infliximab (Remicade) for treating immune-mediated diarrhea and colitis (IMDC), a researcher reported.

Read Article
podcast logo

RheumNow Podcast – Back Talk: Questions from Listeners (10.23.20)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports, survey results and "Back Talk" questions from Rheums.

Read Article
microbes.jpg

Oral Dysbiosis May Antedate Rheumatoid Arthritis

Jack Cush, MD

A study of oral microbiome in anti-cyclic citrullinated peptide (anti-CCP) positive at-risk individuals without synovitis (CCP+at risk) shows dysbiotic subgingival microbiomes and increased abundance of P. gingivalis compared with controls.

Read Article
Liver.hepatitis.jpg

2020 Nobel Prize in Medicine Goes to the Discovery of Hepatitis C

Jack Cush, MD

The Nobel Assembly at Karolinska Institutet has awarded the 2020 Nobel Prize in Physiology or Medicine jointly to Harvey J. Alter, Michael Houghton and Charles M. Rice for the discovery of Hepatitis C virus. These three scientists made a decisive contribution to the fight against blood-borne hepatitis C, a major global health problem that causes cirrhosis and liver cancer in people around the world.

Read Article
Lungs ILD

Comorbidities Impact Disease Activity in Spondyloarthritis

Jack Cush, MD

An analysis of a large population-based cohort of axial spondyloarthritis (axSpA) patients shows that comorbidities are common and are associated with higher disease activity and higher levels of functional impairment.

Read Article
colitis.jpg

Treatment Options for Extraintestinal IBD

Jack Cush, MD

Extraintestinal manifestations (EIMs) frequently accompany inflammatory bowel disease, often augmenting morbidity and mortality are associated with disease activity and may increase the need for surgery or treatment escalation.  A recent review in GUT details the treatment options for patients with EIM.

Read Article
Hepatitis B (Keep)

Hepatitis C Anti-Viral Drug-Induced Arthritis

Jack Cush, MD

Curative direct-acting antiviral therapy (DAAT) for hepatitis-C virus (HCV) infection has been revolutionary, but a novel report shows that nearly one quarter of DAAT treated patients developed new onset or significant worsening of MSK symptoms, despite being negative for hepa

Read Article
podcast logo

RheumNow Podcast – The Bad News That’s Fit to Print (8.21.20)

Jack Cush, MD

Dr Jack Cush reviews the news and journal reports from the past week on RheumNow: filgotinib rejection, delays in diagnosis, metformin benefits COVID, Abx and IBD, and UPA beats MTX.

Read Article
Hypophosphatasia - CPPD/chondrocal, enthesop'y, DISH, exostoses - DDx of Low ALP: milk-alkali, Vit D intoxic'n, Wilson dz, via C def, celiac dz, adyn renal osteodystrophy, Cushing dz, hypothyroid, major sx, MM Rx - asfotase alpha- bone targeted replac't Rx #ACR20 #ACRambassador https://t.co/FJ1355MdKG
Vaneet K Sandhu, MD vksandhumd ( View Tweet)
In patients with Crohn's disease (CD), the presence of HLA-B27 and higher clinical activity of CD were associated with presence of SpA. SpA was present in 21% of early CD patients @RheumNow #ACR20 Abstr#1308

Dr. Antoni Chan synovialjoints ( View Tweet)

Minimum Clinically Important Improvement in Patients with Rheumatoid Arthritis Associates with Gut Microbiome https://t.co/D3ILR57gXY #RA #microbiome that microbiome again

Links:

Peter Nash drpnash ( View Tweet)

Liver damage is NOT an extra-articular manifestation of RA BUT the ff'g factors are associated with liver disease in RA & can complicate management👇@RheumNow #ACR20 https://t.co/RqL69iVJpC
sheila RHEUMarampa ( View Tweet)
Lilly has announced results of Phase 2 SERENITY trial showing the IL-23 inhibitor, mirikizumab, was more effective than PBO at week 12 (PRO and endoscopic outcomes) in moderate to severe active Crohn's disease. Efficacy continued out to week 52 https://t.co/n8Mdeonmas

Links:

Dr. John Cush RheumNow ( View Tweet)

Complement assoc. studied by Petri & Durcan in 2399 SLE pts. 55% had low C3 (pesistently low 4%); 47% low C4 (3% persistently low). Low C4 is weak marker clinical & serological Dz. Low C3 linked w/ renal & serological Dz, Low C3/C4 linked to ACL, CVA, DVT https://t.co/KgF7HNEYu8

Links:

Dr. John Cush RheumNow ( View Tweet)

Danish matched (1:4) cohort study shows COVID-19 pts taking NSAIDs had no greater risk of mortality, hospitalization, ICU admission, mechanical ventilation, or renal replacement therapy; study included 9,236 COVID PCR-positive & 2.7% were on NSAIDs https://t.co/OuUbJ9FxiM

Links:

Dr. John Cush RheumNow ( View Tweet)

Dr Uma Mahadevan and colleagues have published guidelines for managing pregnancy in IBD patients. Rec coordinated care w/ maternal-fetal medicine subspecialist, GI doc, preconception planning, more on treatement https://t.co/oAFcGlOU2y

Links:

Dr. John Cush RheumNow ( View Tweet)

Comparative retrospective study of 251 ANCA+ pts with AAV (MPA or GPA) & severe renal Dz induction Rx with CYC or RTX, +/- PLEX. Remission equally achieved by CTX or RTX; addition of PLEX did not change outcomes. Predictors ESKD and death - eGFR <15 https://t.co/2lbGUS1ahv

Links:

Dr. John Cush RheumNow ( View Tweet)

UK safety reminder that Baricitinib (Olumiant) has an increased risk of diverticulitis (incidence rate 0.16 per 100PY), esp. in those taking Steroids or NSAIDs. https://t.co/IfcV03e1p7

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast - The Bad News That's Fit to Print (8.21.20) Dr Jack Cush reviews this week highlights filgotinib rejection, delays in Diagnosis, metformin benefits COVID, Abx and IBD, and UPA beats MTX https://t.co/1oZtU14VOB https://t.co/rcWlbYVKYn

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×